# Study to Assess the Safety, Tolerability and Explore the Immunogenicity of EG-COVID and EG-COVARo in Healthy Adult Volunteers

> **NCT05188469** · PHASE1,PHASE2 · COMPLETED · sponsor: **EyeGene Inc.** · enrollment: 67 (actual)

## Conditions studied

- COVID-19 Vaccine

## Interventions

- **DRUG:** EG-COVID-003
- **DRUG:** EG-COVID-001
- **DRUG:** A: EG-COVID
- **DRUG:** B: EG-COVID
- **DRUG:** C: EG-COVARo

## Key facts

- **NCT ID:** NCT05188469
- **Lead sponsor:** EyeGene Inc.
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-22
- **Primary completion:** 2024-05-29
- **Final completion:** 2025-02-28
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2025-03-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05188469

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05188469, "Study to Assess the Safety, Tolerability and Explore the Immunogenicity of EG-COVID and EG-COVARo in Healthy Adult Volunteers". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT05188469. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*